Prognostic Significance of ctDNA in HL

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-02

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age \<60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Characterization & Comparison of Drugable Mutations in Primary and Metastatic Tumors, CTCs and cfDNA in MBCpatients

NCT02626039

Metastatic Breast Cancer

COMPLETED

Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients

NCT01623856

Childhood Burkitt Lymphoma Childhood Lymphoblastic Lymphoma

COMPLETED

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

NCT06736613

Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma Stage III High Grade B-Cell Lymphoma +7 more

RECRUITING PHASE2

Optimization of Radiation Protection Through Genomic Analyses

NCT06253338

DNA Cancer Radiation

RECRUITING NA

Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing

NCT06550427

Lymphoma Hodgkin Lymphoma T-cell Lymphoma +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Samples of plasma from peripheral blood will be taken for investigational ctDNA examination during the specific timepoints: at diagnosis, after 2 cycles of initial chemotherapy, at the end of chemotherapy, 3 months after radiotherapy, at the diagnosis of the first relapse, after salvage chemotherapy before ASCT, 3 months after ASCT, at the diagnosis of second relapse and every 3 months during brentuximab vedotin treatment or during nivolumab treatment until progression. The buccal swab for germline DNA extraction will be performed at the time of enrollment into the study. Samples of peripheral blood for EBV-DNA analysis will be obtained from the EBV-positive cHL patients to measure EBV load at the same time-points as ctDNA. Microdissected HRS cells from fresh frozen biopsies at the diagnosis and at the relapse will be used for tumor cells next generation sequencing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prognostic Cancer Model

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard first line treatment, stages I or II without risk factors

Standard first-line treatment that includes 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and involved site radiotherapy of 20 Gy in early clinical stages I or II without risk factors.